Porteus, M. H. A new class of medicines through DNA editing. N. Engl. J. Med. 380, 947–959 (2019).
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020).
Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).
Wang, J. Y. & Doudna, J. A. CRISPR technology: a decade of genome editing is only the beginning. Science 379, eadd8643 (2023).
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).
Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).
Newby, G. A. & Liu, D. R. In vivo somatic cell base editing and prime editing. Mol. Ther. 29, 3107–3124 (2021).
Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 19, 770–788 (2018).
Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome manipulation. Nat. Rev. Genet. 24, 161–177 (2023).
Caruso, S. M., Quinn, P. M., da Costa, B. L. & Tsang, S. H. CRISPR/Cas therapeutic strategies for autosomal dominant disorders. J. Clin. Invest. 132, e158287 (2022).
Suh, S., Choi, E. H., Raguram, A., Liu, D. R. & Palczewski, K. Precision genome editing in the eye. Proc. Natl Acad. Sci. USA 119, e2210104119 (2022).
Yan, A. L., Du, S. W. & Palczewski, K. Genome editing, a superior therapy for inherited retinal diseases. Vis. Res. 206, 108192 (2023).
Du, S. W. & Palczewski, K. Eye on genome editing. J. Exp. Med. 220, e20230146 (2023).
Palczewska, G. et al. Noninvasive multiphoton fluorescence microscopy resolves retinol and retinal condensation products in mouse eyes. Nat. Med. 16, 1444–1449 (2010).
Palczewska, G. et al. Noninvasive two-photon microscopy imaging of mouse retina and retinal pigment epithelium through the pupil of the eye. Nat. Med. 20, 785–789 (2014).
Palczewska, G. et al. Noninvasive two-photon optical biopsy of retinal fluorophores. Proc. Natl Acad. Sci. USA 117, 22532–22543 (2020).
Boguslawski, J. et al. In vivo imaging of the human eye using a 2-photon-excited fluorescence scanning laser ophthalmoscope. J. Clin. Invest. 132, e154218 (2022).
Palczewska, G., Wojtkowski, M. & Palczewski, K. From mouse to human: accessing the biochemistry of vision in vivo by two-photon excitation. Prog. Retin. Eye Res. 93, 101170 (2023).
Ishino, Y., Shinagawa, H., Makino, K., Amemura, M. & Nakata, A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169, 5429–5433 (1987).
Mojica, F. J., Díez-Villaseñor, C., Soria, E. & Juez, G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol. Microbiol. 36, 244–246 (2000).
Jansen, R., Embden, J. D., Gaastra, W. & Schouls, L. M. Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 43, 1565–1575 (2002).
Mojica, F. J., Diez-Villasenor, C., Garcia-Martinez, J. & Soria, E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60, 174–182 (2005).
Bolotin, A., Quinquis, B., Sorokin, A. & Ehrlich, S. D. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151, 2551–2561 (2005).
Pourcel, C., Salvignol, G. & Vergnaud, G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151, 653–663 (2005).
Barrangou, R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712 (2007).
Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I. & Koonin, E. V. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol. Direct 1, 7 (2006).
Makarova, K. S. et al. Evolution and classification of the CRISPR–Cas systems. Nat. Rev. Microbiol. 9, 467–477 (2011).
van der Oost, J., Westra, E. R., Jackson, R. N. & Wiedenheft, B. Unravelling the structural and mechanistic basis of CRISPR–Cas systems. Nat. Rev. Microbiol. 12, 479–492 (2014).
Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl Acad. Sci. USA 109, E2579–E2586 (2012).
Ceccaldi, R., Rondinelli, B. & D’Andrea, A. D. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 26, 52–64 (2016).
Carroll, D. Genome engineering with targetable nucleases. Annu. Rev. Biochem. 83, 409–439 (2014).
Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).
Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538–542 (2015).
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).
Koblan, L. W. et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat. Biotechnol. 36, 843–846 (2018).
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020).
Lin, Q. et al. Prime genome editing in rice and wheat. Nat. Biotechnol. 38, 582–585 (2020).
Nishimasu, H. et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935–949 (2014).
Jiang, F. & Doudna, J. A. CRISPR–Cas9 structures and mechanisms. Annu. Rev. Biophys. 46, 505–529 (2017).
Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729 (2016).
Li, X. et al. Base editing with a Cpf1-cytidine deaminase fusion. Nat. Biotechnol. 36, 324–327 (2018).
Song, Y. et al. Large-fragment deletions induced by Cas9 cleavage while not in the BEs system. Mol. Ther. Nucleic Acids 21, 523–526 (2020).
Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 168, 20–36 (2017).
Ryu, S.-M. et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat. Biotechnol. 36, 536–539 (2018).
Suh, S. et al. Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing. Nat. Biomed. Eng. 5, 169–178 (2021).
Koblan, L. W. et al. In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice. Nature 589, 608–614 (2021).
Newby, G. A. et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature 595, 295–302 (2021).
Choi, E. H. et al. In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration. Nat. Commun. 13, 1830 (2022).
Reichart, D. et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat. Med. 29, 412–421 (2023).
Komor, A. C. et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci. Adv. 3, eaao4774 (2017).
Zafra, M. P. et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat. Biotechnol. 36, 888–893 (2018).
Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883–891 (2020).
Miller, S. M., Wang, T. & Liu, D. R. Phage-assisted continuous and non-continuous evolution. Nat. Protoc. 15, 4101–4127 (2020).
Gaudelli, N. M. et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat. Biotechnol. 38, 892–900 (2020).
Jin, S. et al. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science 364, 292 (2019).
Zuo, E. et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science 364, 289–292 (2019).
Gao, R. et al. Genomic and transcriptomic analyses of prime editing guide RNA–independent off-target effects by prime editors. CRISPR J. 5, 276–293 (2022).
Park, S.-J. et al. Targeted mutagenesis in mouse cells and embryos using an enhanced prime editor. Genome Biol. 22, 170 (2021).
Velimirovic, M. et al. Peptide fusion improves prime editing efficiency. Nat. Commun. 13, 3512 (2022).
Song, M. et al. Generation of a more efficient prime editor 2 by addition of the Rad51 DNA-binding domain. Nat. Commun. 12, 5617 (2021).
Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402–410 (2022).
Zhang, G. et al. Enhancement of prime editing via xrRNA motif-joined pegRNA. Nat. Commun. 13, 1856 (2022).
Anzalone, A. V. et al. Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat. Biotechnol. 40, 731–740 (2022).
Liu, N. et al. HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing. Mol. Ther. Nucleic Acids 29, 36–46 (2022).
Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635–5652.e5629 (2021).
Kevany, B. M. & Palczewski, K. Phagocytosis of retinal rod and cone photoreceptors. Physiology 25, 8–15 (2010).
Kiser, P. D. & Palczewski, K. Retinoids and retinal diseases. Annu. Rev. Vis. Sci. 2, 197–234 (2016).
Flaxman, S. R. et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob. Health 5, e1221–e1234 (2017).
Taylor, A. Ocular immune privilege. Eye 23, 1885–1889 (2009).
Streilein, J. W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3, 879–889 (2003).
Sapino, S. et al. Ocular drug delivery: a special focus on the thermosensitive approach. Nanomaterials 9, 884 (2019).
Dias, M. F. et al. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog. Retin. Eye Res. 63, 107–131 (2018).
Kumar, S. et al. RNA-targeting strategies as a platform for ocular gene therapy. Prog. Retin. Eye Res. 92, 101110 (2023).
Jo, D. H., Bae, S., Kim, H. H., Kim, J. S. & Kim, J. H. In vivo application of base and prime editing to treat inherited retinal diseases. Prog. Retin. Eye Res. 94, 101132 (2023).
Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849–860 (2017).
Bainbridge, J. W. et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N. Engl. J. Med. 372, 1887–1897 (2015).
Jacobson, S. G. et al. Improvement and decline in vision with gene therapy in childhood blindness. N. Engl. J. Med. 372, 1920–1926 (2015).
Cideciyan, A. V. et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl Acad. Sci. USA 110, E517–E525 (2013).
Gardiner, K. L. et al. Long-term structural outcomes of late-stage RPE65 gene therapy. Mol. Ther. 28, 266–278 (2020).
Eghrari, A. O., Riazuddin, S. A. & Gottsch, J. D. Overview of the cornea: structure, function, and development. Prog. Mol. Biol. Transl. Sci. 134, 7–23 (2015).
Meek, K. M., Dennis, S. & Khan, S. Changes in the refractive index of the stroma and its extrafibrillar matrix when the cornea swells. Biophys. J. 85, 2205–2212 (2003).
Liesegang, T. J. Herpes simplex virus epidemiology and ocular importance. Cornea 20, 1–13 (2001).
Iliff, B. W., Riazuddin, S. A. & Gottsch, J. D. The genetics of Fuchs’ corneal dystrophy. Expert Rev. Ophthalmol. 7, 363–375 (2012).
Munier, F. L. et al. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat. Genet. 15, 247–251 (1997).
Farooq, A. V. & Shukla, D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv. Ophthalmol. 57, 448–462 (2012).
Weerasooriya, S., DiScipio, K. A., Darwish, A. S., Bai, P. & Weller, S. K. Herpes simplex virus 1 ICP8 mutant lacking annealing activity is deficient for viral DNA replication. Proc. Natl Acad. Sci. USA 116, 1033–1042 (2019).
Weller, S. K. & Coen, D. M. Herpes simplex viruses: mechanisms of DNA replication. Cold Spring Harb. Perspect. Biol. 4, a013011 (2012).
Yin, D. et al. Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat. Biotechnol. 39, 567–577 (2021).
Wei, A. et al. In vivo CRISPR gene editing in patients with herpes stromal keratitis. Preprint at medRxiv https://doi.org/10.1101/2023.02.21.23285822 (2023).
Gottsch, J. D. et al. Inheritance of a novel COL8A2 mutation defines a distinct early-onset subtype of Fuchs corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 46, 1934–1939 (2005).
Biswas, S. et al. Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. Hum. Mol. Genet. 10, 2415–2423 (2001).
Jun, A. S. et al. An alpha 2 collagen VIII transgenic knock-in mouse model of Fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis. Hum. Mol. Genet. 21, 384–393 (2012).
Meng, H. et al. L450W and Q455K Col8a2 knock-in mouse models of Fuchs endothelial corneal dystrophy show distinct phenotypes and evidence for altered autophagy. Invest. Ophthalmol. Vis. Sci. 54, 1887–1897 (2013).
Uehara, H. et al. Start codon disruption with CRISPR/Cas9 prevents murine Fuchs’ endothelial corneal dystrophy. Elife 10, e55637 (2021).
Lakshminarayanan, R. et al. Clinical and genetic aspects of the TGFBI-associated corneal dystrophies. Ocul. Surf. 12, 234–251 (2014).
Akiya, S., Takahashi, H., Nakano, N., Hirose, N. & Tokuda, Y. Granular-lattice (Avellino) corneal dystrophy. Ophthalmologica 213, 58–62 (1999).
Folberg, R. et al. Clinically atypical granular corneal dystrophy with pathologic features of lattice-like amyloid deposits. A study of these families. Ophthalmology 95, 46–51 (1988).
Moon, J. W. et al. Homozygous granular corneal dystrophy type II (Avellino corneal dystrophy): natural history and progression after treatment. Cornea 26, 1095–1100 (2007).
Watanabe, H. et al. Two patterns of opacity in corneal dystrophy caused by the homozygous BIG-H3 R124H mutation. Am. J. Ophthalmol. 132, 211–216 (2001).
Dinh, R., Rapuano, C. J., Cohen, E. J. & Laibson, P. R. Recurrence of corneal dystrophy after excimer laser phototherapeutic keratectomy. Ophthalmology 106, 1490–1497 (1999).
Lyons, C. J. et al. Granular corneal dystrophy. Visual results and pattern of recurrence after lamellar or penetrating keratoplasty. Ophthalmology 101, 1812–1817 (1994).
Taketani, Y. et al. Repair of the TGFBI gene in human corneal keratocytes derived from a granular corneal dystrophy patient via CRISPR/Cas9-induced homology-directed repair. Sci. Rep. 7, 16713 (2017).
Weinreb, R. N., Aung, T. & Medeiros, F. A. The pathophysiology and treatment of glaucoma: a review. JAMA 311, 1901–1911 (2014).
Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121, 2081–2090 (2014).
Weinreb, R. N. & Khaw, P. T. Primary open-angle glaucoma. Lancet 363, 1711–1720 (2004).
Stone, E. M. et al. Identification of a gene that causes primary open angle glaucoma. Science 275, 668–670 (1997).
Goldenstein, H., Levy, N. S. & Levy, A. P. Haptoglobin genotype and its role in determining heme-iron mediated vascular disease. Pharmacol. Res. 66, 1–6 (2012).
Kasetti, R. B. et al. Autophagy stimulation reduces ocular hypertension in a murine glaucoma model via autophagic degradation of mutant myocilin. JCI Insight 6, e143359 (2021).
Jain, A. et al. CRISPR-Cas9-based treatment of myocilin-associated glaucoma. Proc. Natl Acad. Sci. USA 114, 11199–11204 (2017).
Wu, J. et al. Gene therapy for glaucoma by ciliary body aquaporin 1 disruption using CRISPR-Cas9. Mol. Ther. 28, 820–829 (2020).
Derynck, R. & Budi, E. H. Specificity, versatility, and control of TGF-β family signaling. Sci. Signal. 12, eaav5183 (2019).
Cousins, S. W., McCabe, M. M., Danielpour, D. & Streilein, J. W. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest. Ophthalmol. Vis. Sci. 32, 2201–2211 (1991).
Granstein, R. D. et al. Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation. J. Immunol. 144, 3021–3027 (1990).
Jampel, H. D., Roche, N., Stark, W. J. & Roberts, A. B. Transforming growth factor-beta in human aqueous humor. Curr. Eye Res. 9, 963–969 (1990).
Ozcan, A. A., Ozdemir, N. & Canataroglu, A. The aqueous levels of TGF-beta2 in patients with glaucoma. Int. Ophthalmol. 25, 19–22 (2004).
Yamamoto, N., Itonaga, K., Marunouchi, T. & Majima, K. Concentration of transforming growth factor beta2 in aqueous humor. Ophthalmic Res. 37, 29–33 (2005).
Trivedi, R. H., Nutaitis, M., Vroman, D. & Crosson, C. E. Influence of race and age on aqueous humor levels of transforming growth factor-beta 2 in glaucomatous and nonglaucomatous eyes. J. Ocul. Pharm. Ther. 27, 477–480 (2011).
Pena, J. D., Taylor, A. W., Ricard, C. S., Vidal, I. & Hernandez, M. R. Transforming growth factor beta isoforms in human optic nerve heads. Br. J. Ophthalmol. 83, 209–218 (1999).
Rayana, N. P. et al. Using CRISPR interference as a therapeutic approach to treat TGFβ2-induced ocular hypertension and glaucoma. Invest. Ophthalmol. Vis. Sci. 62, 7 (2021).
Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013).
Thakore, P. I. et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods 12, 1143–1149 (2015).
Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 9, 653–660 (2003).
Wong, T. Y., Cheung, C. M., Larsen, M., Sharma, S. & Simó, R. Diabetic retinopathy. Nat. Rev. Dis. Prim. 2, 16012 (2016).
Hellström, A., Smith, L. E. & Dammann, O. Retinopathy of prematurity. Lancet 382, 1445–1457 (2013).
Jager, R. D., Mieler, W. F. & Miller, J. W. Age-related macular degeneration. N. Engl. J. Med. 358, 2606–2617 (2008).
Guymer, R. H. & Campbell, T. G. Age-related macular degeneration. Lancet 401, P1459–P1472 (2023).
Campochiaro, P. A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 49, 67–81 (2015).
Miller, J. W., Le Couter, J., Strauss, E. C. & Ferrara, N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 120, 106–114 (2013).
Holmgaard, A. et al. In vivo knockout of the Vegfa gene by lentiviral delivery of CRISPR/Cas9 in mouse retinal pigment epithelium cells. Mol. Ther. Nucleic Acids 9, 89–99 (2017).
Koo, T. et al. CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration. Nat. Commun. 9, 1855 (2018).
Ling, S. et al. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nat. Biomed. Eng. 5, 144–156 (2021).
Kim, K. et al. Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. Genome Res. 27, 419–426 (2017).
Chung, S. H. et al. CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization. Mol. Ther. Nucleic Acids 28, 613–622 (2022).
Mitchell, G. A. et al. An initiator codon mutation in ornithine-delta-aminotransferase causing gyrate atrophy of the choroid and retina. J. Clin. Investig. 81, 630–633 (1988).
Duncan, J. L. et al. Inherited retinal degenerations: current landscape and knowledge gaps. Transl. Vis. Sci. Technol. 7, 6 (2018).
Thompson, D. A. et al. Advancing clinical trials for inherited retinal diseases: recommendations from the Second Monaciano Symposium. Transl. Vis. Sci. Technol. 9, 2 (2020).
Georgiou, M., Fujinami, K. & Michaelides, M. Inherited retinal diseases: therapeutics, clinical trials and end points—a review. Clin. Exp. Ophthalmol. 49, 270–288 (2021).
Cideciyan, A. V. et al. Measures of function and structure to determine phenotypic features, natural history, and treatment outcomes in inherited retinal diseases. Annu. Rev. Vis. Sci. 7, 747–772 (2021).
Verbakel, S. K. et al. Non-syndromic retinitis pigmentosa. Prog. Retin. Eye Res. 66, 157–186 (2018).
Hosseini Shabanan, S., Seyedmirzaei, H., Barnea, A., Hanaei, S. & Rezaei, N. Stem cell transplantation as a progressing treatment for retinitis pigmentosa. Cell Tissue Res. 387, 177–205 (2022).
Stingl, K. et al. Subretinal visual implant Alpha IMS—clinical trial interim report. Vis. Res. 111, 149–160 (2015).
Merkle, F. T. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 545, 229–233 (2017).
Petrs-Silva, H. & Linden, R. Advances in gene therapy technologies to treat retinitis pigmentosa. Clin. Ophthalmol. 8, 127–136 (2014).
Bakondi, B. et al. In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol. Ther. 24, 556–563 (2016).
Giannelli, S. G. et al. Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery. Hum. Mol. Genet. 27, 761–779 (2018).
Gumerson, J. D. et al. Restoration of RPGR expression in vivo using CRISPR/Cas9 gene editing. Gene Ther. 29, 81–93 (2022).
Cai, Y. et al. In vivo genome editing rescues photoreceptor degeneration via a Cas9/RecA-mediated homology-directed repair pathway. Sci. Adv. 5, eaav3335 (2019).
Qin, H. et al. Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas. J. Exp. Med. 220, e20220776 (2023).
Tanna, P., Strauss, R. W., Fujinami, K. & Michaelides, M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br. J. Ophthalmol. 101, 25–30 (2017).
Fujinami, K. et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology 122, 326–334 (2015).
Molday, L. L., Rabin, A. R. & Molday, R. S. ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy. Nat. Genet. 25, 257–258 (2000).
Allikmets, R. et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat. Genet. 15, 236–246 (1997).
Molday, R. S., Garces, F. A., Scortecci, J. F. & Molday, L. L. Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration. Prog. Retin. Eye Res. 89, 101036 (2022).
Cideciyan, A. V. et al. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum. Mol. Genet. 13, 525–534 (2004).
Beharry, S., Zhong, M. & Molday, R. S. N-retinylidene-phosphatidylethanolamine is the preferred retinoid substrate for the photoreceptor-specific ABC transporter ABCA4 (ABCR). J. Biol. Chem. 279, 53972–53979 (2004).
Quazi, F., Lenevich, S. & Molday, R. S. ABCA4 is an N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine importer. Nat. Commun. 3, 925 (2012).
Chen, Y. et al. Mechanism of all-trans-retinal toxicity with implications for Stargardt disease and age-related macular degeneration. J. Biol. Chem. 287, 5059–5069 (2012).
Weng, J. et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in abcr knockout mice. Cell 98, 13–23 (1999).
Grieger, J. C. & Samulski, R. J. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J. Virol. 79, 9933–9944 (2005).
Zernant, J. et al. Analysis of the ABCA4 genomic locus in Stargardt disease. Hum. Mol. Genet. 23, 6797–6806 (2014).
Sangermano, R. et al. ABCA4 midigenes reveal the full splice spectrum of all reported noncanonical splice site variants in Stargardt disease. Genome Res. 28, 100–110 (2018).
Scotti, M. M. & Swanson, M. S. RNA mis-splicing in disease. Nat. Rev. Genet. 17, 19–32 (2016).
Cartegni, L., Chew, S. L. & Krainer, A. R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 285–298 (2002).
Ong, C. T. & Corces, V. G. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat. Rev. Genet. 12, 283–293 (2011).
De Angeli, P. et al. Effective splicing restoration of a deep-intronic ABCA4 variant in cone photoreceptor precursor cells by CRISPR/SpCas9 approaches. Mol. Ther. Nucleic Acids 29, 511–524 (2022).
den Hollander, A. I., Roepman, R., Koenekoop, R. K. & Cremers, F. P. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog. Retin. Eye Res. 27, 391–419 (2008).
Kumaran, N., Moore, A. T., Weleber, R. G. & Michaelides, M. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br. J. Ophthalmol. 101, 1147–1154 (2017).
Bennett, J. et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388, 661–672 (2016).
Maguire, A. M. et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126, 1273–1285 (2019).
Rachel, R. A., Li, T. & Swaroop, A. Photoreceptor sensory cilia and ciliopathies: focus on CEP290, RPGR and their interacting proteins. Cilia 1, 22 (2012).
Perrault, I. et al. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. Hum. Mutat. 28, 416 (2007).
Vallespin, E. et al. Frequency of CEP290 c.2991_1655A>G mutation in 175 Spanish families affected with Leber congenital amaurosis and early-onset retinitis pigmentosa. Mol. Vis. 13, 2160–2162 (2007).
den Hollander, A. I. et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am. J. Hum. Genet. 79, 556–561 (2006).
Maeder, M. L. et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat. Med. 25, 229–233 (2019).
Cai, X., Conley, S. M. & Naash, M. I. RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet. 30, 57–62 (2009).
Jo, D. H. et al. CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis. Sci. Adv. 5, eaax1210 (2019).
Jang, H.-K. et al. High-purity production and precise editing of DNA base editing ribonucleoproteins. Sci. Adv. 7, eabg2661 (2021).
Jang, H. et al. Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases. Nat. Biomed. Eng. 6, 181–194 (2022).
Reichel, F. F. et al. AAV8 can induce innate and adaptive immune response in the primate eye. Mol. Ther. 25, 2648–2660 (2017).
Xiong, W. et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc. Natl Acad. Sci. USA 116, 5785–5794 (2019).
Bainbridge, J. W. et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N. Engl. J. Med. 358, 2231–2239 (2008).
Dimopoulos, I. S. et al. Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience. Am. J. Ophthalmol. 193, 130–142 (2018).
Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5, 189ra176 (2013).
Chan, Y. K. et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci. Transl. Med. 13, eabd3438 (2021).
Toral, M. A. et al. Investigation of Cas9 antibodies in the human eye. Nat. Commun. 13, 1053 (2022).
Chandler, R. J., Sands, M. S. & Venditti, C. P. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models. Hum. Gene Ther. 28, 314–322 (2017).
Donsante, A. et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8, 1343–1346 (2001).
Finn, J. D. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227–2235 (2018).
Lyu, P., Javidi-Parsijani, P., Atala, A. & Lu, B. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient ‘hit-and-run’ genome editing. Nucleic Acids Res. 47, e99 (2019).
Mangeot, P. E. et al. Genome editing in primary cells and in vivo using viral-derived nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat. Commun. 10, 45 (2019).
Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250–265.e216 (2022).
Patel, S. R. et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest. Ophthalmol. Vis. Sci. 53, 4433–4441 (2012).
Olsen, T. W. et al. Drug tissue distribution of TUDCA from a biodegradable suprachoroidal implant versus intravitreal or systemic delivery in the pig model. Transl. Vis. Sci. Technol. 9, 11 (2020).
Muya, L., Kansara, V., Cavet, M. E. & Ciulla, T. Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina. J. Ocul. Pharm. Ther. 38, 459–467 (2022).
Yeh, S. et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology 127, 948–955 (2020).
Barakat, M. R. et al. Suprachoroidal CLS-TA plus intravitreal aflibercept for diabetic macular edema: a randomized, double-masked, parallel-design, controlled study. Ophthalmol. Retin. 5, 60–70 (2021).
Campochiaro, P. A. et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmol. Retin. 2, 320–328 (2018).
Jung, J. H., Kim, S. S., Chung, H., Hejri, A. & Prausnitz, M. R. Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space. J. Control Release 352, 472–484 (2022).
Shen, J. et al. Suprachoroidal gene transfer with nonviral nanoparticles. Sci. Adv. 6, eaba1606 (2020).
Ding, K. et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J. Clin. Invest. 129, 4901–4911 (2019).
Kansara, V. S. et al. Suprachoroidally delivered DNA nanoparticles transfect retina and retinal pigment epithelium/choroid in rabbits. Transl. Vis. Sci. Technol. 9, 21 (2020).
Xu, D., Khan, M. A. & Ho, A. C. Creating an ocular biofactory: surgical approaches in gene therapy for acquired retinal diseases. Asia Pac. J. Ophthalmol. 10, 5–11 (2021).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://www.nature.com/articles/s12276-023-01057-2
